Tumor Biology

, Volume 37, Issue 5, pp 5991–5997 | Cite as

High expression of FOXR2 in breast cancer correlates with poor prognosis

  • Haiping Song
  • Wenshan He
  • Xiaoqing Huang
  • Huiqiong Zhang
  • Tao Huang
Original Article

Abstract

Forkhead box protein R2 (FOXR2) is associated with human central nervous system neoplasms. However, the expression level of FOXR2 in breast cancer specimens remains largely unknown. To identify whether FOXR2 can serve as a biomarker for the diagnosis and prognosis of breast cancer, real-time PCR and immunohistochemistry (IHC) staining were utilized to detect the expression of FOXR2. The messenger RNA (mRNA) and protein levels of FOXR2 in breast cancer samples were novelty higher compared to non-tumorous breast tissues. IHC results revealed FOXR2 expression was significantly correlated to classifications tumor size (p = 0.007) and Ki-67 (p = 0.019). The patients with high expression of FOXR2 had a significantly poor prognosis compared to those of low expression (p = 0.003), especially in the patients with tumor size ≥2 cm (p = 0.006) and lymph node metastasis status (p = 0.004). Furthermore, multivariate analysis indicated that FOXR2 expression was an independent prognostic factor for breast cancer patients (p = 0.035). This study first identifies that FOXR2 may be an important molecular marker for diagnosis and prognosis of breast cancer.

Keywords

FOXR2 Breast cancer Prognostic biomarker Immunohistochemistry 

Notes

Compliance with Ethical Standards

Conflicts of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015;65:87–108.Google Scholar
  2. 2.
    Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.CrossRefPubMedGoogle Scholar
  3. 3.
    Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. Lancet Oncol. 2014;15:e351–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, et al. Breast cancer in China. Lancet Oncol. 2014;15:e279–289.CrossRefPubMedGoogle Scholar
  5. 5.
    Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet (London, England). 2009;373:1463–79.CrossRefGoogle Scholar
  6. 6.
    Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29:4273–8.CrossRefGoogle Scholar
  7. 7.
    Freeman JW, McGrath P, Bondada V, Selliah N, Ownby H, Maloney T, et al. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Res. 1991;51:1973–8.PubMedGoogle Scholar
  8. 8.
    Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, et al. High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget. 2015;6:6850–61.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhou X, Zhang J, Yun H, Shi R, Wang Y, Wang W, Lagercrantz SB, Mu K: Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget 2015.Google Scholar
  10. 10.
    Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F: Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast (Edinburgh, Scotland) 2015Google Scholar
  11. 11.
    Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, et al. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: a European organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol: Off J Am Soc Clin Oncol. 2000;18:1075–83.CrossRefGoogle Scholar
  12. 12.
    Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013;10:494–506.CrossRefPubMedGoogle Scholar
  13. 13.
    Cui Y, Niu M, Zhang X, Zhong Z, Wang J, Pang D: High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma. Tumour Biology: The Journal of the International Society for Oncodev Biol Med 2015.Google Scholar
  14. 14.
    Zeidan BA, Townsend PA, Garbis SD, Copson E, Cutress RI: Clinical proteomics and breast cancer. Surgeon: J Royal Coll Surg Edinburgh Irel 2015.Google Scholar
  15. 15.
    Zardavas D, Irrthum A, Swanton C, Piccart M: Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 2015.Google Scholar
  16. 16.
    Katoh M, Katoh M. Human fox gene family (review). Int J Oncol. 2004;25:1495–500.PubMedGoogle Scholar
  17. 17.
    Parry P, Wei Y, Evans G. Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes, Chromosomes Cancer. 1994;11:79–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher 3rd FJ, Emanuel BS, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5:230–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood. 1997;90:3714–9.PubMedGoogle Scholar
  20. 20.
    Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:2672–9.CrossRefGoogle Scholar
  21. 21.
    Katoh M, Katoh M. Identification and characterization of human FOXN6, mouse Foxn6, and rat Foxn6 genes in silico. Int J Oncol. 2004;25:219–23.PubMedGoogle Scholar
  22. 22.
    Santo EE, Ebus ME, Koster J, Schulte JH, Lakeman A, van Sluis P, et al. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene. 2012;31:1571–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Nagel S, Meyer C, Kaufmann M, Drexler HG, MacLeod RA. Deregulated FOX genes in Hodgkin lymphoma. Genes, Chromosomes Cancer. 2014;53:917–33.CrossRefPubMedGoogle Scholar
  24. 24.
    Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45:756–66.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Koso H, Tsuhako A, Lyons E, Ward JM, Rust AG, Adams DJ, et al. Identification of FoxR2 as an oncogene in medulloblastoma. Cancer Res. 2014;74:2351–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Edge SB, Byrd DR, al CCe: American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition, ed 7. Springer, 2009.Google Scholar
  28. 28.
    Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.CrossRefPubMedGoogle Scholar
  29. 29.
    Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both tramp and lady transgenic mice. Cancer Res. 2006;66:1712–20.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Haiping Song
    • 1
  • Wenshan He
    • 1
  • Xiaoqing Huang
    • 1
  • Huiqiong Zhang
    • 1
  • Tao Huang
    • 1
    • 2
  1. 1.Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Breast and thyroid SurgeryUnion HospitalWuhanChina

Personalised recommendations